Drug

Carphenazine

As of the edition of 20 October 2026, Carphenazine is a small molecule: marketed, first approved in 1982 (US); acts on DRD2, HTR2A and HTR2C; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Small molecule
Brand name
Proketazine
First approved
1 January 1982 (US)
Approvals on record
4 in 1 region
Holder of the most recent approval
Pfizer

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Targets

GeneProteinUniProt
DRD2Dopamine receptor D2P14416
HTR2A5-hydroxytryptamine receptor 2AP28223
HTR2C5-hydroxytryptamine receptor 2CP28335

Who has held its approvals

CompanyRoleYears
PfizerApplicant